Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Krystal Biotech Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
KRYS
Nasdaq
8731
https://www.krystalbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Krystal Biotech Inc
Krystal Biotech, Inc. (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why
- Mar 14th, 2024 12:50 pm
Can Krystal Biotech, Inc. (KRYS) Run Higher on Rising Earnings Estimates?
- Mar 8th, 2024 5:20 pm
What Makes Krystal Biotech, Inc. (KRYS) a New Buy Stock
- Mar 8th, 2024 5:00 pm
Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock: Should You Buy?
- Mar 8th, 2024 5:00 pm
Chief Accounting Officer Kathryn Romano Sells 5,000 Shares of Krystal Biotech Inc (KRYS)
- Mar 2nd, 2024 5:00 am
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
- Mar 1st, 2024 12:31 pm
Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2023 Earnings Call Transcript
- Feb 28th, 2024 4:07 pm
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
- Feb 28th, 2024 12:00 pm
Here's Why Momentum in Krystal Biotech, Inc. (KRYS) Should Keep going
- Feb 27th, 2024 1:50 pm
Q4 2023 Krystal Biotech Inc Earnings Call
- Feb 27th, 2024 4:28 am
Krystal Biotech, Inc. (KRYS) Tops Q4 Earnings and Revenue Estimates
- Feb 26th, 2024 2:25 pm
Krystal Biotech Inc (KRYS) Reports Strong Q4 and Full Year 2023 Financial Results
- Feb 26th, 2024 1:31 pm
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- Feb 26th, 2024 1:00 pm
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
- Feb 20th, 2024 12:00 pm
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
- Feb 13th, 2024 12:00 pm
Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa
- Feb 8th, 2024 12:00 pm
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
- Feb 1st, 2024 12:00 pm
Chief Accounting Officer Kathryn Romano Sells 2,500 Shares of Krystal Biotech Inc
- Jan 25th, 2024 4:01 am
We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
- Jan 15th, 2024 2:47 pm
Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®
- Jan 4th, 2024 12:00 pm
Scroll